LifeStance Lifts Full-Year 2026 Outlook Across Every Metric
LFST has more than doubled off its 52-week low of $4.79.
Summary
LifeStance raised its full-year 2026 outlook across all financial metrics, now guiding to revenue of $1.74B-$1.76B. The company reported Q3 revenue of $455.9M and Q3 adjusted EBITDA of $68.4M. It generated $37.0M of operating cash flow in Q3 and $170.0M over the nine months ended September 30, 2026, with no prior-year comparison provided, and ended the quarter with $218.8M in cash against $255.5M of net long-term debt. The raise builds on Q2 2026 revenue of $435.4M, up 26% year over year, and $23.6M of net income. The stock trades near $13.50, well above the $12.29 where TPG and Summit Partners sold 22.25M shares in September's secondary.
At the time of this announcement, LFST was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $4.79 to $14.31. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.